Department of Brain Disease, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
J Immunol Res. 2022 Jul 8;2022:1709360. doi: 10.1155/2022/1709360. eCollection 2022.
Vascular cognitive impairment (VCI) has emerged as the second major disease responsible for dementia, and there is still a lack of effective treatment methods for this disorder to date. Clinical medications have found that Yisui Fuyongtang (YSFYT) Decoction is effective in improving neurological signs and learning-memory functions in patients who develop white matter lesions and whole brain atrophy. To clarify the effect and molecular regulation mechanism of YSFYT Decoction on model rats, this research analyzed the influence of YSFYT Decoction on the learning-memory ability and lipid metabolism of rats based on behavioral and biochemical analysis. Further pathology and protein detection methods were adopted to investigate the action of YSFYT Decoction on the neurons in the hippocampus of model rats and the regulation of the brain derived neurotrophic factor (BDNF)-tyrosine protein kinase receptor B (TrkB) signaling pathway. Compared with the VCI group, after YSFYT Decoction administration, the ratio of swimming time in the platform, number of crossing the platform, number of active avoidance, and proportion of active avoidance of the rats were markedly increased, whereas the response latency was substantially reduced ( < 0.05). Biochemical tests indicated that contents of lipoprotein lipase (LPL), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) of the model rats in YSFYT Decoction treatment group were greatly reduced, whereas those of total antioxidant capacity (T-AOC), glutathione peroxidase (GSH-PX), catalase (CAT), malondialdehyde (MDA), and superoxide dismutase (SOD) were elevated ( < 0.05). Additionally, Bcl-2 expression in YSFYT Decoction treatment group was significantly increased, but neuron apoptosis of the hippocampus tissue was reduced. Meanwhile, neuron number was apparently higher than that in VCI model group. Following Yisui Decoction treatment, expressions of growth-associated protein 43 (GAP43), synaptophysin (SYP), postsynaptic density 95 (PSD95), NMDAR subunit 2B (NR2B), BDNF, TrkB, phospho-mitogen-activated protein kinase (p-MAPK), extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K), and phospho-protein kinase B (p-AKT) were markedly elevated. Taken together, YSFYT Decoction could activate the BDNF-TrkB signaling pathway, elevate Bcl-2 expression, and minimize neuronal apoptosis in hippocampus, thereby improving the behavioral characteristics and biochemical indicators of the VCI rat model.
血管性认知障碍(VCI)已成为导致痴呆的第二大疾病,迄今为止,针对这种疾病仍然缺乏有效的治疗方法。临床药物研究发现,益髓复元汤(YSFYT)对改善有白质病变和全脑萎缩的患者的神经体征和学习记忆功能有效。为了阐明 YSFYT 汤对模型大鼠的作用及分子调控机制,本研究通过行为学和生物化学分析,分析了 YSFYT 汤对大鼠学习记忆能力和脂代谢的影响。进一步采用病理学和蛋白质检测方法,研究了 YSFYT 汤对模型大鼠海马神经元的作用以及脑源性神经营养因子(BDNF)-酪氨酸蛋白激酶受体 B(TrkB)信号通路的调节。与 VCI 组相比,YSFYT 汤给药后,大鼠在平台游泳时间的比例、穿越平台次数、主动回避次数和主动回避比例显著增加,而反应潜伏期明显缩短(<0.05)。生化测试表明,YSFYT 汤治疗组模型大鼠脂蛋白脂肪酶(LPL)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)的含量显著降低,而总抗氧化能力(T-AOC)、谷胱甘肽过氧化物酶(GSH-PX)、过氧化氢酶(CAT)、丙二醛(MDA)和超氧化物歧化酶(SOD)的含量升高(<0.05)。此外,YSFYT 汤治疗组 Bcl-2 表达明显增加,但海马组织神经元凋亡减少。同时,神经元数量明显高于 VCI 模型组。在益髓汤治疗后,生长相关蛋白 43(GAP43)、突触小体蛋白(SYP)、突触后密度 95(PSD95)、N-甲基-D-天冬氨酸受体亚单位 2B(NR2B)、BDNF、TrkB、磷酸化丝裂原活化蛋白激酶(p-MAPK)、细胞外信号调节激酶(ERK)、磷脂酰肌醇 3-激酶(PI3K)和磷酸化蛋白激酶 B(p-AKT)的表达明显升高。综上所述,YSFYT 汤可激活 BDNF-TrkB 信号通路,提高 Bcl-2 表达,减少海马神经元凋亡,从而改善 VCI 大鼠模型的行为特征和生化指标。